Company Overview of Igenica, Inc.
Igenica, Inc., a biopharmaceutical company, engages in the discovery and development of antibody-based therapeutics for the treatment of cancer. It develops recombinant monoclonal antibodies and treatments for multiple oncology indications. The company was founded in 2008 and is based in Burlingame, California.
863 Mitten Road
Burlingame, CA 94010
Founded in 2008
Key Executives for Igenica, Inc.
Vice President of Research
Vice President of Process Development
Compensation as of Fiscal Year 2015.
Igenica, Inc. Key Developments
Igenica Biotherapeutics Signs Oncology Research Deal with MedImmune
Oct 28 15
Igenica Biotherapeutics has signed an oncology research agreement with AstraZeneca's subsidiary MedImmune. The companies will assess the potential of antibody-drug conjugates (ADCs) targeting Surface Antigen in Leukemia (SAIL). SAIL is a novel cell surface protein with high prevalence of expression in several hematologic malignancies and solid tumors. Preclinical data have supported the selective targeting of tumors expressing SAIL with ADCs. Igenica will provide its anti-SAIL antibodies, including IGN786, and its SNAP ADC drug linker, while MedImmune will contribute its anti-tumor payload. Both the companies will then jointly investigate the resulting novel ADC in preclinical studies. MedImmune will have an option to an exclusive worldwide license to anti-SAIL antibodies and antibody-drug conjugates that arise from the partnership. Igenica will have an exclusive option fee. If MedImmune exercises its option, the company will also receive an upfront license fee, clinical, regulatory and commercialization milestones, and royalties on net sales. The development and commercialization costs will be funded by MedImmune under a license agreement.
Igenica Biotherapeutics, Inc. Presents at BIO-Europe 2015, Nov-02-2015
Oct 1 15
Igenica Biotherapeutics, Inc. Presents at BIO-Europe 2015, Nov-02-2015 . Venue: Munich, Germany.
Igenica, Inc. Presents at Boston Biotech NY/NJ CEO Conference, Nov-12-2014 04:10 PM
Oct 27 14
Igenica, Inc. Presents at Boston Biotech NY/NJ CEO Conference, Nov-12-2014 04:10 PM. Venue: Apella, 450 East 29th Street, New York, New York, United States. Speakers: Mary Haak-Frendscho, Chief Executive Officer and Director.
Similar Private Companies By Industry
Recent Private Companies Transactions
September 29, 2015
May 22, 2015
January 8, 2015